Northern Trust’s Lyell Immunopharma LYEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$607K Hold
30,280
﹤0.01% 3537
2025
Q4
$932K Buy
30,280
+2,152
+8% +$48.2K ﹤0.01% 3415
2025
Q3
$457K Buy
28,128
+9,484
+51% +$108K ﹤0.01% 3682
2025
Q2
$165K Sell
18,644
-46,110
-71% -$420K ﹤0.01% 3998
2025
Q1
$697K Sell
64,754
-757
-1% -$9.27K ﹤0.01% 3432
2024
Q4
$839K Sell
65,511
-2,293
-3% -$45.5K ﹤0.01% 3463
2024
Q3
$1.87M Sell
67,804
-1,648
-2% -$48.4K ﹤0.01% 3048
2024
Q2
$2.01M Sell
69,452
-2,647
-4% -$126K ﹤0.01% 2895
2024
Q1
$3.22M Sell
72,099
-1,676
-2% -$71.8K ﹤0.01% 2736
2023
Q4
$2.86M Sell
73,775
-384
-0.5% -$13.8K ﹤0.01% 2802
2023
Q3
$2.18M Buy
74,159
+2,446
+3% +$116K ﹤0.01% 2893
2023
Q2
$4.56M Sell
71,713
-14,826
-17% -$820K ﹤0.01% 2554
2023
Q1
$4.08M Sell
86,539
-22,888
-21% -$1.22M ﹤0.01% 2580
2022
Q4
$7.59M Buy
109,427
+7,491
+7% +$744K ﹤0.01% 2199
2022
Q3
$14.9M Buy
101,936
+41,722
+69% +$5.65M ﹤0.01% 1695
2022
Q2
$7.85M Buy
60,214
+7,593
+14% +$776K ﹤0.01% 2208
2022
Q1
$5.32M Buy
52,621
+42,042
+397% +$5.09M ﹤0.01% 2550
2021
Q4
$1.64M Sell
10,579
-113
-1% -$25.2K ﹤0.01% 3321
2021
Q3
$3.17M Buy
+10,692
New +$3.2M ﹤0.01% 3030

Other funds holding LYEL

Northern Trust's LYEL Position: Q1 2026 in Review

Northern Trust held its Lyell Immunopharma (LYEL) position steady in Q1 2026 at 30,280 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #3537.

Northern Trust first reported a position in LYEL in Q3 2021 and has held it in 19 quarters since. The position peaked at $14.9M in Q3 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Northern Trust held 30,280 shares of Lyell Immunopharma worth $607K as of Q1 2026.
  • Northern Trust left its Lyell Immunopharma share count unchanged in Q1 2026.
  • Lyell Immunopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3537 holding.
  • Northern Trust first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 19 quarters since.
  • Northern Trust's Lyell Immunopharma position peaked at $14.9M in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.